Explore

How the Central Executive Network Manages Tough Tasks

How the Central Executive Network Manages Tough Tasks

The central executive network, also known as the lateral frontoparietal network, plays a crucial role in cognitive control and problem-solving. Thi...

Neuropixels Opto Device Revolutionizes Neuronal Function Research

Neuropixels Opto Device Revolutionizes Neuronal Function Research

A new technology, Neuropixels Opto, has been developed to integrate electrophysiology and optogenetics, allowing researchers to simultaneously record and manipulate neuronal activity in the brain. This device, co-developed by UCL scientists, features around 1,000 recording sites on an ultra-thin probe, enabling high-resolution monitoring of individual neurons and large neural networks. The technology promises to advance the understanding of neural circuits and neurological conditions such as Alzheimer's and schizophrenia.

How the Salience Network Helps the Brain Prioritize Stimuli

How the Salience Network Helps the Brain Prioritize Stimuli

The salience network is a crucial component of the human brain, playing a significant role in how we process and respond to stimuli. This network i...

Neurosurgeon Develops FDA-Approved Device to Combat Rheumatoid Arthritis

Neurosurgeon Develops FDA-Approved Device to Combat Rheumatoid Arthritis

Dr. Kevin J. Tracey, a neurosurgeon, has developed a device called the SetPoint System, which has been approved by the FDA to treat rheumatoid arthritis (RA). The device, implanted in the neck, uses electrical signals to stimulate the vagus nerve, reducing inflammation in RA patients. This innovation stems from Tracey's career-long dedication to understanding inflammation, sparked by the tragic death of a baby in his care in 1985. The SetPoint System offers a new treatment avenue for the 1.5 million Americans suffering from RA, providing relief where traditional medications have failed.

SystImmune Presents Promising Phase 1 Data for BL-M14D1 in Small-Cell Lung Cancer at ASCO

SystImmune Presents Promising Phase 1 Data for BL-M14D1 in Small-Cell Lung Cancer at ASCO

SystImmune Presents Promising Phase 1 Data for BL-M14D1 in Small-Cell Lung Cancer at ASCO

Lysoway Therapeutics Receives Grant to Advance Parkinson's Disease Research

Lysoway Therapeutics Receives Grant to Advance Parkinson's Disease Research

Lysoway Therapeutics has been awarded a $3.4 million grant from The Michael J. Fox Foundation for Parkinson's Research to advance its TMEM175 agonist program. The funding will support preclinical and translational studies of Lysoway's small-molecule TMEM175 agonists, which aim to improve lysosomal function and cellular resilience in Parkinson's disease. The research will focus on evaluating the therapeutic potential of TMEM175 activation in maintaining lysosomal pH and autophagic capacity. This grant highlights the growing recognition of TMEM175 as a promising target for Parkinson's disease treatment.

Kimera Labs Achieves ISO Certifications for Quality Management in Manufacturing

Kimera Labs Achieves ISO Certifications for Quality Management in Manufacturing

Kimera Labs Achieves ISO Certifications for Quality Management in Manufacturing

Researchers Identify Tau Protein's Role in Neuronal Death in Alzheimer's Disease

Researchers Identify Tau Protein's Role in Neuronal Death in Alzheimer's Disease

A recent study conducted by researchers at Zhejiang University and Xiamen University has uncovered a mechanism by which tau protein aggregates contribute to neuronal death in Alzheimer's disease. The study, published in Nature Neuroscience, reveals that these tau clumps can reactivate transposable DNA elements within neurons, leading to cell death. The research utilized genetically engineered mice, known as PS19 mice, which exhibit abnormal tau aggregation similar to that seen in Alzheimer's patients. The study found that tau aggregates disrupt heterochromatin, a tightly packed form of DNA, leading to the activation of genes that produce Z-RNAs. These Z-RNAs then activate Z-DNA-binding protein 1 (ZBP1), which is involved in inflammation and cell death. The findings suggest that inhibiting ZBP1 could be a potential therapeutic strategy to combat neurodegeneration in tauopathies.

Study Reveals How Literacy Alters Brain's Processing of Spoken Language

Study Reveals How Literacy Alters Brain's Processing of Spoken Language

A recent study published in the journal Cortex has revealed that learning to read significantly alters the brain's pathways for processing spoken language. The research, led by Mariana P. Nucci from the University of São Paulo, found that adults with formal literacy training utilize a specialized region on the right side of the brain to identify isolated speech sounds. This neurological response is absent in individuals with limited reading education. The study involved participants from São Paulo, Brazil, including highly educated young and older adults, as well as older adults with low levels of formal education. Using functional magnetic resonance imaging, the researchers observed that literate individuals performed better in phonological awareness tasks, particularly when listening to unfamiliar languages, compared to their illiterate counterparts.

Akeso's VEGF/PD-1 Therapy Shows Promise in Lung Cancer Survival

Akeso's VEGF/PD-1 Therapy Shows Promise in Lung Cancer Survival

Akeso's VEGF/PD-1 Therapy Shows Promise in Lung Cancer Survival

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Humacyte Reports Positive Long-Term Dialysis Data, Boosting Market Position

Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients

Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients

Revolution Medicines Begins Distribution of Experimental Pancreatic Cancer Drug to Patients